Sector: Pharmaceuticals & Biotechnology - Healthcare
BSE Code: 543322
NSE Symbol: ALIVUS
ISIN: INE03Q201024
📄 Alivus Life Sciences Receives Tax Assessment Order for FY 2022–23 - Assessment order received from Income Tax Department on March 20, 2026, at approximately 7:30 PM. - Pertains to financial year 2022–23 (Assessment Year 2023–24). - Tax demand raised: ₹2,60,67,810, including applicable interest.…
📅 Alivus Life Sciences Sets One-on-One Meeting with Millennium Capital - Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) is holding a one-on-one meeting with Millennium Capital Management - The meeting is scheduled for March 17, 2026, in Mumbai - The meeting will be conduct…
📅 Alivus Life Sciences Sets Investor & Analyst Meetings • Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Limited) is holding meetings with investors and analysts • Three scheduled meetings: March 12, 2026 (virtual) with ICICI Direct, and March 16, 2026 (in-person in Mumbai) with Green …
🔥 Alivus Life Sciences Reports Fire Incident at Dahej Facility • Fire incident occurred on February 14, 2026 at Dahej, Gujarat manufacturing facility • Incident confined to one of seven production blocks, affecting only intermediate manufacturing facilities • API manufacturing in the same block w…
🔥 Fire at Alivus Life Sciences API Plant in Dahej, Gujarat • Fire broke out at Alivus Life Sciences Limited's API Plant in Dahej, Gujarat, on February 14, 2026, at around 23:00 Hrs. • Three injuries were reported as a result of the incident. • The fire was brought under control within one hour, b…
📅 Alivus Life Sciences Announces Investor & Analyst Meetings in Mumbai - Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) will attend investor/analyst meetings on February 10, 11, and 26, 2026. - Meetings include: MANTHAN - Systematix India Annual Conference (Feb 10, in-pers…
Alivus Life Sciences Q3 Results: Record Revenue & Margin Growth 📈 - Q3 revenue: Rs. 673 crores, up 14.4% QoQ and 4.8% YoY - EBITDA margin reached record 36.4% in Q3, up 510 bps YoY - CDMO business grew 100% QoQ and 85.3% YoY - High single-digit revenue growth guidance maintained for FY'26 - EBITD…
Alivus Life Sciences Receives Partial GST Relief Order 📄 - Alivus Life Sciences received a GST order from the Joint Commissioner of State Tax (Appeals), Solapur, dated January 29, 2026. - The order provides partial relief on GST demand for FY 2019-20. - Original tax demand reduced from ₹5.21 cror…
Alivus Life Sciences Sets Investor & Analyst Meetings for Feb 2-4, 2026 📅 - Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) is holding one-on-one meetings with investors and analysts from February 2 to 4, 2026. - Meetings are scheduled with Catamaran (virtual), Vyom Partner…
Alivus Life Sciences Q3 FY2025-26 Earnings Call Now Available 🎧 - Alivus Life Sciences (formerly Glenmark Life Sciences) has released the audio recording of its Q3 FY2025-26 earnings call. - The earnings call took place on January 22, 2026. - The recording is accessible on the company's official …
Alivus Life Sciences Q3 FY26: Strong Revenue & Margin Growth 📈 - Q3 FY26 revenue: ₹6,729M (14.4% QoQ, 4.8% YoY growth) - EBITDA: ₹2,452M (26.5% QoQ, 22.1% YoY growth) - PAT: ₹1,503M (15.5% QoQ, 9.7% YoY growth) - Gross margins improved to 58.9% (+120 bps QoQ, +330 bps YoY) - EBITDA margins rose t…
Alivus Life Sciences Reports Record Q3FY26 Results & Expansion Plans 🚀 - Record Q3FY26 revenue: ₹6,729 Mn (14.4% QoQ, 4.8% YoY growth) - Q3FY26 EBITDA: ₹2,452 Mn (26.5% QoQ, 22.1% YoY growth), with record 36.4% margin - Q3FY26 PAT: ₹1,503 Mn (15.5% QoQ, 9.7% YoY growth), 22.3% margin - 9MFY26 rev…
Alivus Life Sciences Q3 Results: Steady Growth in Revenue & Profit 📈 - Revenue from operations in Q3 rose to ₹6,728.89M (vs. ₹6,418.44M YoY). - Total income for Q3 reached ₹6,868.17M (up from ₹6,523.00M YoY). - Profit before tax improved to ₹1,983.92M (vs. ₹1,851.47M YoY). - Net profit (after tax…
Alivus Life Sciences Allots 55K Employee Stock Options 📈 - 55,000 equity shares allotted under 'Employee Stock Option Scheme, 2021'. - Face value per share: ₹2. - Paid-up capital rises from 12,26,81,348 shares (₹24,53,62,696) to 12,27,36,348 shares (₹24,54,72,696). - Announcement date: January 21…
Alivus Life Sciences Q3 FY2025-26 Earnings Call: Key Details 📅📞 - Earnings call scheduled for January 22, 2026, from 6:00 p.m. to 7:00 p.m. (IST). - Discussion will focus on Q3 FY2025-26 financial performance. - Universal dial-in numbers provided for participants from multiple countries (India, …
Alivus Life Sciences (formerly Glenmark) to Review Q3 & 9M FY26 Results 📅📊 - Board meeting on January 22, 2026 to approve Unaudited Financial Results for quarter and nine months ended December 31, 2025. - Trading Window closure from December 31, 2025 to January 24, 2026 (both days inclusive) for…
Alivus Life Sciences Sets Key Investor Meeting in Mumbai 📅 - Alivus Life Sciences Ltd (formerly Glenmark Life Sciences) has scheduled a meeting with Kosh Wealth Management. - The in-person meeting is set for December 30, 2025, in Mumbai. - Format: One-on-one session with company representatives. …
🔍 Alivus Life Sciences Sets Up Investor & Analyst Meetings – Key Dates Inside - Alivus Life Sciences (formerly Glenmark Life Sciences) has scheduled investor and analyst meetings. - December 23, 2025: Virtual one-on-one meetings with Omega Portfolio and Mount Intra Finance. - December 29, 2025: V…
Alivus Life Sciences (Formerly Glenmark) Sets Up Investor Meeting 🗓️ - Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Ltd) has a virtual meeting scheduled with Choice India on December 18, 2025. - Meeting details may be subject to change due to unforeseen circumstances. - Scrip code: 5…
Alivus Life Sciences Sets Investor & Analyst Meetings 🗓️ - Alivus Life Sciences (formerly Glenmark Life Sciences) schedules investor and analyst meetings. - Meetings set for December 16 to December 18, 2025. - Participants include Unique PMS, Yes Securities, JM Financial, Systematix, and SIMPL. -…